For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Agios Pharmaceuticals (AGIO) been one of those stocks this ...

Shares of Agios Pharmaceuticals AGIO fell 11% on Thursday after the company announced that the FDA had extended the review timeline for the supplemental new drug application (sNDA) seeking label ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against the other ...

Agios Pharmaceuticals, Inc. (AGIO) announced on Thursday that the U.S. Food and Drug Administration has extended the review period for its drug Pyrukynd, intended for the treatment of adult patients ...

Shares of Agios Pharmaceuticals (AGIO) bounced back with a ~10% rise on Thursday as Leerink Partners upgraded the biotech, arguing that the stock, which dropped over 50% in the previous session in ...

Drugmaker Agios Pharmaceuticals (NASDAQ: AGIO) is positioning to win the FDA's approval of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting. That's ...

Agios Pharmaceuticals (NASDAQ: AGIO) was a standout stock in the healthcare sector on Hump Day. Investors eagerly snapped up the company's shares after it unveiled its latest quarterly earnings report ...

Agios Pharmaceuticals’ mitapivat has shown tremendous promise as a treatment for sickle cell disease. It’s been so promising, in fact, that the U.S. Food and Drug Administration is allowing the ...